Abstract | BACKGROUND: METHODS: RESULTS: In part 1 the endotoxic shock model showed a significant reduction in TNF levels in the spironolactone-treated group compared to the non-treated group, suggesting that spironolactone acts as a TNF inhibitor. In part 2 spironolactone-treated rats did not demonstrate significantly less alveolar bone destruction compared to non-treated rats. CONCLUSIONS: The insignificant effect of spironolactone treatment could be explained by the fast metabolism of spironolactone and that spironolactone does not completely inhibit TNF production in rats. Moreover, many other cytokines and mediators involved in alveolar bone destruction may account for the lacking response to spironolactone.
|
Authors | M C B Grauballe, B H Bentzen, M Björnsson, D Moe, T E N Jonassen, K Bendtzen, K Stoltze, P Holmstrup |
Journal | Journal of periodontal research
(J Periodontal Res)
Vol. 40
Issue 3
Pg. 212-7
(Jun 2005)
ISSN: 0022-3484 [Print] United States |
PMID | 15853966
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Lipopolysaccharides
- Tumor Necrosis Factor-alpha
- Spironolactone
|
Topics |
- Administration, Oral
- Alveolar Bone Loss
(drug therapy, prevention & control)
- Animals
- Lipopolysaccharides
(administration & dosage)
- Male
- Maxillary Diseases
(drug therapy, prevention & control)
- Periodontitis
(drug therapy)
- Rats
- Shock, Septic
(blood, drug therapy)
- Spironolactone
(therapeutic use)
- Tumor Necrosis Factor-alpha
(analysis, antagonists & inhibitors)
|